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ABSTRACT Efficient vaccination against infectious agents and tumors depends on specific antigen targeting to dendritic cells
(DCs). We report here that biosafe coronavirus-based vaccine vectors facilitate delivery of multiple antigens and immunostimu-
latory cytokines to professional antigen-presenting cells in vitro and in vivo. Vaccine vectors based on heavily attenuated mu-
rine coronavirus genomes were generated to express epitopes from the lymphocytic choriomeningitis virus glycoprotein, or hu-
manMelan-A, in combination with the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-
CSF). These vectors selectively targeted DCs in vitro and in vivo resulting in vector-mediated antigen expression and efficient
maturation of DCs. Single application of only low vector doses elicited strong and long-lasting cytotoxic T-cell responses, pro-
viding protective antiviral and antitumor immunity. Furthermore, human DCs transduced withMelan-A-recombinant human
coronavirus 229E efficiently activated tumor-specific CD8 T cells. Taken together, this novel vaccine platform is well suited to
deliver antigens and immunostimulatory cytokines to DCs and to initiate andmaintain protective immunity.
IMPORTANCE Vaccination against infectious agents has protectedmany individuals from severe disease. In addition, prophylactic and,
most likely, also therapeutic vaccination against tumorswill savemillions frommetastatic disease. This study describes a novel vaccine
approach that facilitates delivery of viral or tumor antigens to dendritic cells in vivo. Concomitant immunostimulation via the cyto-
kine granulocyte-macrophage colony-stimulating factor (GM-CSF)was achieved throughdelivery by the same viral vector. Single im-
munizationwith only lowdoses of coronavirus-based vaccine vectorswas sufficient to elicit (i) vigorous expansion and optimal differ-
entiation ofCD8T cells, (ii) protective and long-lasting antiviral immunity, and (iii) prophylactic and therapeutic tumor immunity.
Moreover, highly efficient antigen delivery to humanDCswith recombinant human coronavirus 229E and specific stimulation of hu-
manCD8T cells revealed that this approach is exceptionallywell suited for translation into human vaccine studies.
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Vaccination against viral infections has saved millions of lives byprotecting many individuals from diseases such as measles, ru-
bella, mumps, and polio. However, there is a growing need not only
todevelop improvedvaccinesagainst suchacute infectionsbutalso to
generate therapeutic vaccines which can stimulate specific immune
responses to persistent viruses such as the human immunodeficiency
virus or the human hepatitis C virus (1, 2). Likewise, novel ap-
proaches forvaccinationagainst tumorswhichcounteract the immu-
nosuppression associated with cancer are needed (3). There is com-
pelling evidence that CD8 cytotoxic T cells are crucial players in the
protective immune response against viral infections and tumors (4).
Novel vaccine approaches should thus be rigorously evaluated for
their ability to maximally expand antigen-specific CD8 T cells, to
induce their optimaldifferentiation into effectorCD8Tcells, and to
elicit long-lasting protective memory (4).
A major bottleneck in the development of new and effective
vaccines is the delivery of antigens to dendritic cells (DCs) (5, 6),
which sample the antigen, transport immunogenic components
to secondary lymphoid organs, and initiate and maintain T and B
cell responses. The excellent capacity of DCs to prime protective
antiviral T cell responses has been shown in vivo (7–9). Likewise,
several preclinical studies demonstrated that efficient antitumor
immunity can be induced using adoptive transfer of DCs (10–12).
Although individualized adoptive transfer of antigen-loaded DCs
is feasible and, to a certain extent, efficient in clinical applications
to humans (13), off-the-shelf vaccines that permit targeted deliv-
ery of antigens to DCs in vivo have become a major focus in vac-
cine development. Consequently, the description of cell surface
molecules that, for example, exhibit a rather specific expression by
DCs has fueled the development of antibody-based targeting
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strategies (14–16). These protein-based vaccines generate CD4
T cell and B cell responses against a range of different antigens.
However, antigen coupling to antibodies is a major limitation
for the induction of CD8 T cell responses which are strictly
dependent on cross-presentation (5, 17). In contrast, viral vec-
tors encoding immunogenic antigens can deliver their genetic
cargo directly into DCs, thus generating antigenic peptides in
infected cells and allowing for efficient loading of major histo-
compatibility complex (MHC) class I molecules. Among the
currently most exploited virus systems that facilitate antigen
delivery to DCs are adenoviral (18, 19), lentiviral (20), arena-
viral (21), and alphaviral (22, 23) systems. However, major
impediments of these vectors are frequent off-target transduc-
tion, resulting in antigen presentation by parenchymal cells
outside secondary lymphoid organs, and limited cloning ca-
pacity for the insertion of multiple or large antigens. For exam-
ple, the strong tropism of adenoviral vectors for hepatocytes,
with95% of the genetic material being deposited in the liver,
leads to generation of functionally impaired CD8 T cells (24,
25). Major efforts are thus required to engineer adenoviral vec-
tors with improved specificity for the relevant antigen-
presenting cells (12, 19). Likewise, lentiviral vectors preferen-
tially infect cells other than DCs, and redirection of their target
cell tropism is warranted (26). An additional potential imped-
FIG 1 Generation, propagation, and in vitro target cell tropism ofMHV-based vaccine vectors. (A) Schematic representation of theMHV-A59 genome and the
highly attenuated MHV vectors. (B) Packaging concept for the generation of replication-competent but propagation-deficient MHV particles. (C) Growth
kinetics of the indicatedMHV vectors in 17ECl20 packaging cells. Cells were infected at anMOI of 1, and titers in supernatants were determined at the indicated
time points (means of results from triplicatemeasurements standard errors of themeans [SEM]). (D) Replication of the indicatedMHV vectors orMHV-A59
wild-type virus in L929 cells, bone marrow-derived DCs, and peritoneal macrophages. The indicated cells (106/ml, MOI 1) were infected, and replication was
monitored by titration of supernatants on 17ECl20 packaging cells (mean  SEM of duplicate measurements). One representative experiment out of three is
displayed. (E) Transduction of L929 cells and peritoneal macrophages with anMHV-GP or MHV-GM/GP vector (MOI 1). Green fluorescence was recorded
6 h posttransduction. Original magnification,400. (F, G) Stimulation of DCs by GM-CSF-expressing vectors. Bone marrow-derived DCs (106) from B6 mice
were transduced with the indicated MHV-based vector (MOI  1) or left untreated. Cells were harvested 12 h later and stained for CD11c, CD86, and CD40
expression. (F) Representative dot plots indicating the high transduction efficacy. Values in the upper right quadrant indicate percentages of EGFP cells. (G)
Expression of theDC activationmarkers CD86 andCD40 on untreated CD11c cells (shaded), on CD11c EGFP cells (thick black line), or onCD11cEGFP
cells (thick red line). Values in the histograms represent mean fluorescence intensity of the respective population.
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iment for the use of DNA-based viral vectors in clinics is
their potential to integrate genomic material into the host
genome (27).
Coronaviral vectorsdisplay anumberof features that clearlyover-
come these limitations. First, replication of these positive-stranded
RNA viruses is restricted to the cytoplasm, without a DNA interme-
diary, making insertion of viral sequences into the host cell genome
unlikely. Second, there is accumulating knowledge on how to atten-
uate coronaviruses inorder toprovidebiosafe vectors (28, 29).Third,
coronavirus genomes with sizes of 27 to 31 kb represent the largest
autonomously replicatingRNAsknown todate and thusoffer a clon-
ing capacity ofmore than 6 kb. Fourth, the unique transcription pro-
cess generates 6 to 8 subgenomicmRNAs encoding the four canoni-
cal structural proteins and various numbers of accessory proteins,
which canbe replaced to encodemultipleheterologousproteins (30).
Finally, andcertainlymost intriguing, cell surface receptorsofhuman
andmurine coronaviruses are expressedonhumanandmurineDCs,
respectively (31, 32).
The present study describes the generation and evaluation of
rationally designed coronavirus-based vectors that efficiently tar-
get antigens and immunostimulatorymolecules to DCs.We show
that murine-coronavirus-based vectors can deliver multiple
antigens and immunostimulatory cytokines almost exclusively
to CD11c DCs within secondary lymphoid organs. Immuni-
zation with only low numbers of particles elicited potent CD8
T cell responses that provided long-lasting protection against
viral challenge. Moreover, single appli-
cation of these novel viral vectors gen-
erated prophylactic and therapeutic im-
munity against metastatic melanoma.
Induction of cytotoxic T lymphocytes
(CTL) directed against the human
Melan-A (Mel-A) antigen in HLA-A2-
transgenic mice and efficient human-
DC-mediated stimulation of Mel-A-
specific CTL through Mel-A-
recombinant human coronavirus 229E
(HCoV-229E) indicates that
coronavirus-mediated gene transfer to
DCs represents a versatile approach for
murine and human immunization
against both viral infection and cancer.
RESULTS
Design and propagation of biosafe
coronavirus-based vaccine vectors. To
assess immunogenicity and to ensure
maximal safety of coronavirus-based
multigene vaccine vectors, we have ratio-
nally designed a series of prototype vec-
tors based on the mouse hepatitis virus
strain A59 (MHV-A59) (Fig. 1A). With
regard to safety, we introduced three ba-
sic modifications to obtain replication-
competent, but attenuated and
propagation-deficient, MHV-based vec-
tors. First, we deleted all MHV accessory
genes (NS2,HE, gene4, gene5a), a strategy
that attenuates MHV in the natural host
(29) and provides space for the introduc-
tion of heterologous genes. Second, we
removed 99 nucleotides within the replicase gene-encoded se-
quence of nonstructural protein 1 (nsp1), because this deletion
has been shown to greatly reduce MHV pathogenicity while re-
taining immunogenicity (28). Finally, we deleted structural geneE
to restrict proper particle formation (33). Indeed, although repli-
cation of wild-typeMHV tomaximal titers occurred around day 5
postinfection, in vivo replication of MHV vectors could not be
detected (not shown). Consequently, there was also noMHV vec-
tor replication detectable in livers or brains (not shown). The high
safety profile of MHV-based vectors is further illustrated by the
fact that the health status of C57BL/6 (B6) or different immuno-
deficient mice was not affected, even if the vectors were applied at
high doses (see Fig. S1 in the supplemental material).
In order to test the coronavirus-based vaccine concept and to
develop a vaccine that provides strong CTL responses, in terms of
both magnitude and longevity, we used the CTL epitope gp33-41
(the region from residues 33 to 41), derived from the lymphocytic
choriomeningitis virus (LCMV) glycoprotein, and the Mel-A26-35
analog peptide, derived from the humanMelan-A/melanoma an-
tigen recognized by T cells 1 (MART1) protein (Fig. 1A). The CTL
epitopes were cloned as fusion proteins with the enhanced green
fluorescent protein (EGFP) (34, 35), and the corresponding genes,
designated GP-EGFP and EGFP–Mel-A, were cloned between the
MHVvector-borne spike andmembrane genes. Since appropriate
stimulation of DCs is critical for the generation of efficient T cell
FIG 2 In vivo antigen delivery to dendritic cells by MHV-based vaccine vectors. B6 mice were immu-
nized i.v. with 106 PFUMHV-GP or MHV-GM/GP or were left untreated. Spleens were collected after
18 h, 24 h, or 36 h and digested with collagenase, and low-density cells were isolated by gradient
centrifugation. Expression of CD11c, CD11b, CD8, CD86, and CD40 onDCs was determined by flow
cytometry. (A)Time course analysis of EGFP expression inCD11cDCs. Pooled data from two separate
experiments (5mice per time point). Values in the upper right quadrant indicatemean percentages plus
SEM of EGFP cells. (B) Expression of CD11b and CD8 in transduced DCs at 18 h postinfection.
Values in the quadrants represent percentages of CD11b or CD8 cells in the EGFP CD11cDCs.
(C) DC activation assessed as CD86 and CD40 upregulation on EGFP CD11c and EGFP CD11c
cells at the 18-h time point. Values in the histograms represent mean fluorescence intensity of the
respective population. PBS, phosphate-buffered saline.
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responses (36) and hence an indispensable component of ratio-
nally designed vaccines, we inserted the gene encoding themurine
granulocyte-macrophage colony-stimulating factor (GM-CSF)
between the MHV vector-borne replicase and spike genes
(Fig. 1A). To propagate the MHV-based viral vectors to high ti-
ters, we produced a packaging cell line based on murine 17clone1
cells that express theMHV envelope (E) protein under the control
of the Tet-off system (Fig. 1B). This strategy enabled us to restore
efficient vector particle formation and propagation in order to
obtain vector stocks of106/ml (Fig. 1C).
DC-specificdelivery of coronavirus vector-encoded antigens
and cytokines.To assessMHVvector growth kinetics on cells that
do not express the E protein, we transduced L929 cells, bone
marrow-derived CD11cDCs, or perito-
neal macrophages with the MHV vectors
and compared growth kinetics to that of
wild-type MHV-A59. In accordance with
reports on E gene-deficient MHV-A59
(37), the growth of the MHV-based vec-
tor was greatly impaired in L929 cells
(Fig. 1D). Most importantly, however,
MHV vector transduction did not result
in particle release in peritoneal macro-
phages and DCs, demonstrating that the
lack of the E protein preventsMHVprop-
agation in primary cells (Fig. 1D). MHV
vectors elicited significant EGFP expres-
sion in transduced L929 cells and perito-
neal macrophages (Fig. 1E) and in
CD11c DCs (Fig. 1F). Notably, vector-
mediated GM-CSF expression resulted in
DC activation and maturation, as shown
by upregulation of CD86 and CD40 on
CD11c cells (Fig. 1G). The rapid pro-
duction of GM-CSF in L929 cells, perito-
nealmacrophages, andDCs following ex-
posure to the cytokine-encoding vectors
(Fig. S2) shows that MHV vectors can be
used to simultaneously express antigens
and immunostimulatory cytokines in tar-
get cells.
To further determine the cellular tro-
pism of MHV-based vectors, we trans-
duced splenocytes from C57BL/6 (B6)
mice with MHV-GM/GP in vitro and an-
alyzed EGFP expression by flow cytom-
etry. Neither CD4 nor CD8 T cells
were susceptible to MHV-GM/GP trans-
duction (not shown), whereas antigen-
presenting cells, such as B cells (CD19),
macrophages (F4/80 or CD11b), and
DCs (CD11C), displayed green fluores-
cence indicative of MHV vector-
mediated EGFP expression (see Fig. S3A
in the supplementalmaterial). In order to
evaluate whether targeting of DCs and
macrophages is also achievable in vivo, we
injected (intravenously [i.v.]) 106 PFU of
MHV-GP orMHV-GM/GP into B6mice
and analyzed EGFP expression of spleno-
cytes by flow cytometry. EGFP expression was detectable mainly
in CD11c CD11b DCs and CD11c CD8 DCs (Fig. 2A and
B and see Fig. S3B in the supplemental material). Finally, we as-
sessed the effects of MHV vector-mediated GM-CSF expression
on DC stimulation and activation in vivo. Slightly elevated GM-
CSF levels in spleens could be observed following application of
the MHV-GM/GP vector (Fig. S4A), whereas GM-CSF levels in
serum remained below the limit of detection (not shown). Con-
comitant immunization with MHV-GP and MHV-GM/Mel-A
vectors revealed that the supply of GM-CSF in trans, i.e., via the
MHV-GM/Mel-A vector was not sufficient to achieve the maxi-
mal activation of gp34-specific CD8T cells. Only whenGM-CSF
was encoded by the same vector that expressed the GP-EGFP pro-
FIG 3 Evaluation of antiviral CD8 T cell responses. (A) B6 mice were immunized i.v. with either 200
PFULCMV, 105 PFUMHV-GP, or 105 PFUMHV-GM/GP. Splenocytes were analyzed on day 7 postin-
fection (p.i.) for expression of CD8 and reactivity with H2-Db/gp33 or H2-Kb/gp34 tetramers, and
CD8 splenocytes were analyzed for gp33- and gp34-specific IFN- production. Values in the upper
right quadrants represent percentages of Tet cells SEM (upper row) or percentages of IFN- cells
 SEM (lower row) in the CD8 T-cell compartment (mean SEM; 3 mice per group). (B, C) Efficacy
of MHV-based vectors in inducing antiviral CD8 T cell responses. B6 mice were immunized i.v. with
the indicated doses ofMHV-GP orMHV-GM/GP. Tetramer analysis and IFN- ICS was performed on
day 7 postimmunization (mean SEM; 3 mice per group). (C) Importance of the route of immuniza-
tion. B6 mice were immunized with 105 PFU MHV-GM/GP. Tetramer analysis and IFN- ICS were
performed on day 7 postimmunization (mean SEM; 2 to 6 mice per group, pooled from 2 different
experiments). (D)Duration of vector-inducedCD8T cell response. B6micewere immunizedwith 105
PFU MHV-GM/GP or MHV-GP. Tetramer analysis and IFN- ICS were performed at the indicated
time points (mean SEM; 3mice per group). (E) In vivo restimulation ofMHV vector-induced CD8
memory T cells. B6mice were immunized with 105 PFUMHV-GM/GP or injected with PBS.Mice were
boosted on day 65 i.v. with 106 PFUMHV-GM/GP or injected with PBS. Tetramer analysis and IFN-
ICS were performed on day 4 after the booster immunization (mean  SEM; 4 mice per group). i.n.,
intranasal.
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tein (MHV-GM/GP), was themaximal immune response induced
(Fig. S4B). Furthermore, MHV-GM/GP-induced GM-CSF ex-
pression did not alter the cellular composition in spleens (see
Fig. S5 in the supplemental material). These results support the
notion that vector-encoded GM-CSF acts locally in the microen-
vironment of transducedDCs.However, in vivo transductionwith
both MHV-GP and MHV-GM/GP mediated DC maturation,
with upregulation of CD86 and CD40 (Fig. 2C). Notably, appli-
cation of MHV-GP vectors led to a less efficient transduction of
DCs in vivo, which lasted only for roughly 18 h (Fig. 2A), suggest-
ing that GM-CSF supplied by MHV vectors fosters DC survival
and, to a lesser extent, DC maturation and thereby potentiates
their antigen presentation function.
Antiviral CTL responses following coronavirus vector im-
munization. Infection with LCMV is characterized by a vigorous
expansion of antiviral CTL and persistence of protective memory
CTL (38), which are directed against several epitopes. Two differ-
ent epitopes are present in the gp33-41 region of the LCMVGP that
was used in two of our constructs: the H2-Db-binding gp33-41 (39)
and the H2-Kb-binding gp34-41 (40). On day 7 after LCMV infec-
tion, significant numbers of CD8 T cells could be detected by
MHC tetramer analysis and intracellular cytokine secretion (ICS)
assay (Fig. 3A). It is important to note that the gp33 ICS records
both gp33- and gp34-specific CD8 T cells. It appears that the
processing of the GP-EGFP transgene in theMHV-GP andMHV-
GM/GP vectors permitted the preferential generation of gp34-
specific CD8 T cells to a magnitude comparable to that seen
during acute LCMV infection (Fig. 3A). The GM-CSF-encoding
MHV vector proved to be highly efficient in the induction of an-
tiviral CTL, even at rather low doses of 103 and 104 PFU (Fig. 3B).
Since the intermediate dose of 105 PFU of MHV-GM/GP led to
optimal induction of gp34-specific CTL, we used this dose to as-
sess whether application via different routes would influence the
induction of transgene-specific CTL. As shown in Fig. 3C, all
routes of immunization elicited robust CD8 T cell responses,
with intraperitoneal (i.p.), subcutaneous (s.c.), intramuscular
(i.m.), and i.v. injection being the most efficient means of appli-
cation. BothMHV-GP- andMHV-GM/GP-inducedCD8T cells
displayed full effector function because gp34 peptide-loaded tar-
get cells were rapidly eliminated in immunized hosts (see Fig. S6A
in the supplemental material). MHV vector-induced CD8 T cell
responses were detectable for more than 65 days after immuniza-
tion (Fig. 3D) and, most importantly, could be restimulated in
vivo by immunization with the same vector (Fig. 3E).
Protection against LCMVchallenge requires high levels of appro-
priately activated CD8 T cells (38). In order to assess the efficacy of
MHV vector-based immunization for protection against viral chal-
lenge, B6 mice were immunized with graded doses of the MHV-GP
or MHV-GM/GP vector and challenged 7 days later with LCMV.
Comparable to the high level of CD8T cell induction (Fig. 3), com-
pleteprotectionwasobserved inmiceafter immunizationwithadose
of 105 PFU (Fig. 4A). Remarkably, as few as 103 PFU of MHV-
GM/GP still led to a3-log reduction of LCMV titers in spleens on
day 4 postchallenge (Fig. 4A). Protection against LCMV was long-
lasting because mice were still protected after more than 2 months
following immunization with 105 PFU MHV-GM/GP via the i.v.
(Fig. 4B), s.c., or i.m. route (see Fig. S6B in the supplemental mate-
rial).Moreover, theMHV-GM/GP vaccine elicited complete protec-
tionagainst i.p. challengewithLCMVGPrecombinant vaccinia virus
(VV) (Fig. 4C). Likewise, immunization with MHV-GP provided
substantial protection against this heterologous viral infection
(Fig. 4C). It is important to indicate that the MHV-based vaccine,
even when GM-CSF was encoded by the vector, provided specific
protectionbecause replicationof the unrelated recombinant vaccinia
virus expressing vesicular stomatitis virus (VSV) Indiana glycopro-
tein (VV-INDG) was not affected (Fig. 4C). Taken together, these
results revealed that theMHV-based vector system is highly efficient
in generating protective antiviral immunity and that the incorpora-
tion of GM-CSF into the vaccine significantly augmented its protec-
tive capacity.
Prophylactic and therapeutic antitumor immunization. In
order to evaluate whether MHV vector-based vaccination elic-
its prophylactic and therapeutic tumor immunity, we resorted
to a rapidly growing B16 melanoma model which provides
compatibility with the LCMVGP system through expression of
a gp33 minigene (B16F10-GP cells) (41). I.v. injection of 5 
105 B16F10-GP or parental B16F10 cells in control B6 mice
resulted in metastatic growth of tumor cells in lungs (Fig. 5A).
Immunization with either 105 PFU MHV-GP or 105 PFU
MHV-GM/GP completely blocked the growth of B16F10-GP
tumor cells, whereas metastasis formation of the parental
B16F10 cells was not affected (Fig. 5A). Application of graded
doses of MHV-GP or MHV-GM/GP revealed the high efficacy
of this vaccination approach in the prophylactic setting, i.e.,
104 MHV-GP or only 103 PFUMHV-GM/GP were sufficient to
prevent the growth of the melanoma cells (Fig. 5B). A long-
lasting memory response that provided significant protection
against B16F10-GP challenge had been generated following
MHV-GM/GP immunization (Fig. 5C). Moreover, the potent
CD8 T cell response elicited through MHV-GM/GP immuni-
zation mediated therapeutic tumor immunity (Fig. 5D), i.e.,
the tumor burden in lungs of B6 mice was significantly reduced
even when the vaccine was applied after the tumors had started
to form metastatic nodules, indicating that CD8 T cell re-
FIG 4 Induction of long-lasting protective antiviral immunity. (A) B6 mice
were either left untreated (Ctrl) or immunized (i.v.) with the indicated doses of
MHV-GP or MHV-GM/GP. Seven days later, mice were challenged i.v. with
200PFULCMV.Viral titers in spleens (means SEM)were determined 4 days
after LCMV challenge using a focus-forming assay onMC57 cells (4 to 6 mice
per group, pooled from 2 different experiments). (B) Duration of protective
antiviral immunity. B6 mice were immunized with 105 PFU MHV-GM/GP
and challenged i.v. with 200 PFU LCMV at the indicated time points. Viral
titers in spleens (mean SEM) were determined 4 days after LCMV challenge
using a focus-forming assay ofMC57 cells (4 to 6mice per group, pooled from
2 different experiments). (C) Female B6 mice were either left untreated (Ctrl)
or immunized (i.v.) with 105 PFU MHV-GP or 105 PFU MHV-GM/GP.
Seven days later, mice were challenged i.p. with 2  106 PFU LCMV GP-
recombinant vaccinia virus (VV-G2) or vesicular stomatitis virus
glycoprotein-recombinant vaccinia virus (VV-INDG). Vaccinia virus titers
(mean SEM) in ovaries were determined 5 days after challenge infection (4
mice per group). ND, not detectable.
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sponses elicited by the novel MHV vectors can exert forceful
antitumor activity.
To further substantiate the finding thatMHV vectors can induce
potent and relevant antitumor CD8 T cell responses, we employed
the human HLA-A2-restricted Melan-A/MART1 system, in which
immune responses against the Mel-A26-35 analog peptide can be
monitored in HLA-A2.1-transgenic (A2DR1) mice (42). A2DR1
mice were immunized i.v. with either 105 PFUMHV–Mel-A or 105
PFU MHV-GM/Mel-A, and Mel-A-specific CD8 T cell responses
were recorded using tetramer analysis and ICS. As shown in Fig. 6A,
both vectors elicited substantial CD8 T cell responses. Time course
experiments following i.v. application of MHV-GM/Mel-A revealed
a strong global expansion of CD8 T cells (nearly 10-fold) and a
massive expansion ofMel-A-specificCD8T cells, with 2 106 cells
per spleen being tetramer positive and 6 106 cells per spleen secret-
inggamma interferon (IFN-) (Fig. 6B).TheMel-A-specificCD8T
cell population showed a typical contraction after day 7, and a stable
memory population had been established
by day 28 postimmunization (Fig. 6B).
During the acute phase following MHV-
GM/GP immunization,90% of the Mel-
A-specificCD8Tcells haddownregulated
CD62L (Fig. 6C). As expected, memory
CD8 T cells reacquired CD62L expres-
sion, indicating establishment of a central
memory CD8 T cell population. Overall,
these results underline that the
coronavirus-based vaccination approach,
particularly in combination with the im-
munostimulatory cytokine GM-CSF, pro-
vides efficient means for the induction of
CD8T cell responses against a human tu-
mor antigen.
Delivery of tumor antigen to human
DCs. Human coronavirus-based vectors
permit specific transfer of multiple genes
to DCs because the receptor of HCoV-
229E, human aminopeptidase N (hAPN
or CD13) (43), is expressed on human
DCs (31). Furthermore, we have demon-
strated previously that HCoV-229E-
based vectors can transduce immature
and mature human DCs with reporter
genes such as the firefly luciferase gene
(30). Here we assessed whether HCoV-
229E-mediated delivery of theMel-A26-35
analog peptide to HLA-A2 human DCs
would specifically stimulate human Mel-
A-specific CD8 T cells. To this end, we
generated two recombinant human
coronaviruses, designated HCoV–
Mel-A and HCoV–GP-EGFP, through
replacement of HCoV-229E accessory
gene 4 with the gene for the EGFP–Mel-
A26-35 or gp33-EGFP fusion protein, re-
spectively (Fig. 7A). As shown in
Fig. 7B, EGFP expression was readily
detectable in both human immature
andmature DCs after HCoV–Mel-A in-
fection. Time course analysis of human
mature DCs infected with HCoV–Mel-A or HCoV–GP-EGFP
revealed that high levels of EGFP expression can be reached as
early as 9 h postinfection (see Fig. S7 in the supplemental mate-
rial). Finally, mature DCs infected with HCoV–Mel-A or HCoV–
GP-EGFP were employed to stimulateMel-A26-35-specific human
T cells. As shown in Fig. 7C, we observed efficient stimulation of
the tumor-specific T cells by HCoV–Mel-A, indicating that
HCoV-229E, with its pronounced tropism for human CD13-
expressing DCs, represents a particularly promising tool for ge-
netically delivering antigens to human antigen-presenting cells.
DISCUSSION
This study describes a novel vaccine approach that facilitates de-
livery of viral or tumor antigens to DCs in vivo. Concomitant
immunostimulation—here via the cytokine GM-CSF—was
achieved through targeted transduction by the same viral vector.
Single immunization with only 104 to 105 MHV-based particles
FIG5 Prevention and immunotherapeutic treatment ofmetastaticmelanoma. (A) B6mice were either
left untreated (Ctrl) or immunized (i.v.) with either 105 PFU MHV-GP or MHV-GM/GP. Seven days
later, mice were challenged with 5 105 LCMV gp33-recombinant B16F10-GP tumor cells or parental
B16F10 tumors cells i.v. Tumor growth in lungs was recorded on day 12 after tumor challenge. Macro-
scopic pictures show representative lungs from 1 out of 3 mice per group. (B) Efficacy of MHV-based
vectors in generating prophylactic tumor immunity. B6 mice were immunized i.v. with the indicated
doses of MHV-GP or MHV-GM/GP or infected i.v. with 200 PFU LCMV and challenged as described
for panel A, and numbers of metastatic foci per lung were determined on day 12 (means SEM; 6mice
per group, pooled from 2 experiments). (C) Duration of protective antitumor immunity. B6mice were
immunized i.v. with 105 PFUMHV-GM/GP, infected i.v. with 200 PFU LCMV, or left untreated (Ctrl).
Mice were challenged as described for panel A, and tumor growth was determined on day (d) 12
postchallenge (means  SEM; 4 to 6 mice per group, pooled from 2 experiments). (D) Therapeutic
antitumor immunity. B6 mice received 5 105 LCMV gp33-recombinant B16F10-GP tumor cells i.v.
andwere immunizedwith 105 PFUMHV-GM/GP i.v. either on the same day (day 0) or 4 or 8 days later.
Photographs of dorsal and ventral sides of affected lungs are displayed. Disease severity was determined
on day 20 after tumor inoculation; data indicate affected lung surfaces as determined by black pixel
counting (mean SEM; 4mice per group). Statistical analysis was performed using Student’s t test (***,
P 0.001; **, P 0.01; *, P 0.05; a P value of0.05 was not significant). ND, not detectable.
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was sufficient to elicit (i) vigorous expansion and optimal differ-
entiation of CD8T cells, (ii) protective and long-lasting antiviral
immunity, and (iii) prophylactic and therapeutic tumor immu-
nity. Moreover, highly efficient antigen delivery to human DCs
with recombinantHCoV-229E and specific stimulation of human
CD8 T cells revealed that this approach is exceptionally well
suited for translation into human vaccine studies.
Targeting of antigen to DCs in vivo can be achieved by several
means (5). The use of viral vectors appears to be the superior strategy
for eliciting innate activation of the immune system and optimal in-
duction of CD8 T cells (24). However, many virus vector systems
are still limited in their ability to induce broad and long-lasting im-
mune responses. For example, recombinant adenoviruses have been
studied intensively as vaccine candidates mainly because they can be
produced to high titers. Nevertheless, high doses of recombinant ad-
enovirus vectors have to be applied to in-
duce an immune response, most probably
because they target antigensmainly to non-
lymphoid organs, such as the liver (25, 44).
In contrast to viral vectors based on DNA
viruses (45), positive-stranded RNA virus-
based vectors that replicate in the cyto-
plasm are considered safe vectors. The
safety is well documented for vectors based
on widely used vaccine strains, such as po-
liovirus (46), or virus-like particles (VLPs)
that containrepliconRNAsdevoidof struc-
tural genes (47). It should be noted that ap-
plication of the MHV-based vectors de-
scribed in this study was always well
tolerated and did not result in any sign of
disease or adverse side effect irrespectively
of dosage and route of MHV-based vector
application, even in immunodeficient
mouse strains. Finally, it is noteworthy that
although some RNA virus-based vectors
are able to target DCs (21), their cloning
capacity is, in sharp contrast to that of
coronavirus-based vectors, generally re-
stricted and the expression of multiple an-
tigens and/or immunostimulatory cyto-
kines is limited.
The novel coronavirus-based vaccine
platform described here displayed a high
immunogenicity. It is very likely that it is
the pronounced tropism of the MHV-
based vectors for DCs and macrophages
within secondary lymphoid organs that
guarantees efficient activation of primary
CD8 T cell responses. In vivo imaging
studies have shown that CD169
CD11c DCs at the subcapsular sinus of
lymph nodes efficiently present viral an-
tigen to naïve T cells (48). Likewise,
CD169 macrophages at the same loca-
tion are able to collect viral antigen from
the lymph and present antigen to follicu-
lar B cells (49). Moreover, a recent study
from our laboratory has revealed that
type I IFN-mediated protection of DCs
and macrophages from cytopathic effects of MHV infection is
essential to buy time for mounting a protective CD8 T cell re-
sponse (50). It remains to be resolved which factors—besides the
presence of the MHV receptor on DCs (32)—confers the prefer-
ential infection of the relevant antigen-presenting cells within sec-
ondary lymphoid organs. For further adaptation of the
coronavirus-based vectors to the human system, some of the es-
sential parameters have been clarified; i.e., the receptor of HCoV-
229E is expressed mainly on monocytes and DCs within second-
ary lymphoid organs (31), and recombinant HCoV-229E
efficiently targets humanDCs irrespective of theirmaturation sta-
tus. It is important to add that HCoV-229E is one of at least four
human coronaviruses that are transmitted via mucosal surfaces
and are associated with mild upper respiratory tract infections
(common cold). Furthermore, the low pathogenic potential of
FIG 6 Assessment of anti-Melan-A/MART1 CD8 T cells in A2DR1 mice. (A) Transgenic mice
expressing the human HLA-A2.1 molecule were immunized i.v. with 105 PFUMHV–Mel-A or MHV-
GM/Mel-A. At day 7 postinfection, splenocytes andmononuclear blood cells were analyzed for expres-
sion of CD8 and reactivity with HLA-A2/Mel-A26-35 tetramers and for Mel-A26-35-specific IFN- and
TNF- production. Values in the upper right quadrants represent mean percentages of Tet cells 
SEM in blood and spleen, percentages of IFN- cells SEM, or percentages of TNF- cells SEM
in the CD8 T-cell compartment (3 mice per group). (B) Time course of Mel-A26-35-specific CD8
T-cell responses in A2DR1 mice following i.v. immunization with 105 PFU MHV-GM/Mel-A. Total
numbers of CD8 T cells, tetramer-binding Mel-A26-35-specific CD8 T cells, and Mel-A26-35-specific
IFN-CD8 T cells were determined at the indicated time points postimmunization (means SEM;
3 mice per group). (C) Differentiation of tetramer-binding Mel-A26-35-specific CD8 T-cells as deter-
mined by CD62L expression at the indicated time points postimmunization (means SEM; 3mice per
group). Data are from one representative experiment out of three. hi, high-level expression.
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HCoV-229E is corroborated by the fact that HCoV-229E was pas-
saged in volunteers in the 1960s without any serious side effects.
These features, together with the pronounced DC-targeting capa-
bilities demonstrated in this report, should encourage the devel-
opment of coronavirus-based vectors for human use.
A second major advantage of the coronavirus-based vaccina-
tion strategy is the large cloning capacity of the vectors, which
offers the possibility of incorporating immunostimulatory cyto-
kines. GM-CSF-encoding MHV vectors led to strong production
of this cytokine in both macrophages and DCs in vitro. Interest-
ingly, GM-CSF expression in vivo appeared to be largely restricted
to locally transduced cells, as no gross differences in GM-CSF
levels in spleen or serumwere observed afterMHV-GM/GPvector
immunization. It is most likely that GM-CSF-induced changes
within the microenvironment of transduced macrophages and
DCs are decisive for the optimal induction of effector andmemory
CD8 T cell responses. Indeed, it is the optimally stimulated ex-
pression of costimulatory molecules on antigen-presenting cells,
together with sufficient innate immune stimulation, that deter-
mines the primary expansion and the maintenance of antiviral
CD8 T cells (51). Accordingly, such non-TCR signals (“signals 2
and 3”) are considered key components of rationally designed
vaccines (4). The lack of such optimally composed stimuli in a
vector-based vaccine most likely requires very elaborate prime-
boost immunization regimes, as was recently shown for a com-
bined adenovirus/MVA vaccination approach (52), and/or sub-
stantially increased vector doses to achieve efficacy, as for example
in vaccination with the latest versions of DC-adapted lentivirus
vectors, where application of 5  107 to 10  107 particles was
required to achieve significant expansion of ovalbumin-specific
CD8 T cells in mice (53).
In conclusion, we provide here a versatile vaccine platform
based on coronaviruses that achieved the efficient generation of
protective immunity, shown as long-lasting memory against viral
challenge and induction of both prophylactic and therapeutic tu-
mor immunity. The biology of coronaviruses and the rational
modification of these viral RNA vectors harbor significant poten-
tial for future development.
MATERIALS AND METHODS
Ethics statement. Experiments were performed in accordance with fed-
eral and kantonal guidelines under permission numbers SG07/62, SG07/
63, 07/64, and 07/71 following review and approval by the Kantonal Vet-
erinary Office (St. Gallen, Switzerland).
Mice, cells, and viruses. C57BL/6 mice were obtained from Charles
River Laboratories (Sulzfeld, Germany). A2DR1 mice were kindly sup-
plied by F. A. Lemonnier (Pasteur Institute, Paris, France) (42). All mice
weremaintained in individually ventilated cages andwere used at between
6 and 9 weeks of age. L929 and CV-1 cells were purchased from the Eu-
ropean Collection of Cell Cultures. MC57 and BSC40 cells were obtained
from R. M. Zinkernagel (University of Zürich, Switzerland). D980R cells
were a kind gift from J. F. Smith (Imperial College London, London,
United Kingdom). 17clone1 cells were a kind gift from S. G. Sawicki
(Medical University of Ohio, Toledo, OH). Huh7 cells were a kind gift
from V. Lohmann (University of Heidelberg, Germany). The LCMVWE
strain was obtained from R.M. Zinkernagel (Universität Zürich, Switzer-
land). Recombinant vaccinia virus expressing LCMV glycoprotein 2 (VV-
G2) was originally obtained from B. H. Bishop (University of Oxford,
United Kingdom), and recombinant vaccinia virus expressing vesicular
stomatitis virus Indiana glycoprotein (VV-INDG)was originally obtained
from B. Moss (National Institutes of Health, Bethesda, MD). Titration
and determination of antiviral protection assays have been performed as
described previously (7). Further details can be found in Text S1 in the
supplemental material.
Cloning and generation of recombinant MHV-based vectors and
human coronaviruses. Genomic RNA of recombinant MHV-based vec-
tors and recombinant HCoVs were produced from cloned cDNA using
purified vaccinia virus DNA as the template for in vitro transcription as
described previously (54). A detailed description of all cloning steps, se-
quence information, and production of recombinant coronavirus parti-
cles can be found in Text S1 in the supplemental material.
Isolation of dendritic cells and macrophages, flow cytometry, im-
munofluorescence. Generation of bone marrow-derived DCs and flow cy-
tometric analysiswere performed as describedpreviously (50). Further infor-
mation on these procedures can be found in Text S1 in the supplemental
material. For immunofluorescence analysis of viral replication, 2 105 L929
cells or peritoneal macrophages were seeded in slide chambers and trans-
FIG 7 Transduction of human DCs with Melan-A-recombinant HCoV-
229E. (A) Schematic representation of the modified HCoV-229E viruses en-
coding different antigen cassettes. (B) Human monocyte-derived DCs, either
immature ormature, were infected with recombinantHCoV-229E (MOI 1)
encoding the EGFP–Mel-A26-35 fusion protein. Cells were harvested 12 h later
and stained for the indicated surface molecules. (Left) Maturation status as
assessed by CD14 and CD86 costaining. Values in the lower right panels indi-
cate percentages of CD14 CD86 cells. (Right) Transduction efficacy mea-
sured as EGFP expression. Values in the upper right panel indicate percentages
of CD13 EGFP cells. The results of one representative experiment out of 4,
with DCs derived from different donors, are shown. (C) Activation of a Mel-
A-specific T cell clone byMel-A26-35-presenting DCs. Mature DCs were either
left untreated, pulsed with theMel-A26-35 peptide, transduced with GP-EGFP-
recombinant HCoV-229E, or transduced with EGFP–Mel-A26-35-
recombinant HCoV-229E (MOI 1). DCs and T cells were cocultured for 6 h
at a 4:1 ratio, and activation of the T cells was assessed by IFN- ICS. Values in
the histogram indicate percentages of IFN--expressing T cells. The results of
one representative experiment out of three are shown.
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ducedwithMHV-GP orMHV-GM/GP (MOI 1). At the time points indi-
cated in Fig. 1, the slides were acetone fixed, blocked with the Fc-blocking
antibody 2.4G2, and stained with anti-EGFP Alexa 488 (BioLegend). Images
were acquired using a Leica DMRAmicroscope and processed using Adobe
Photoshop (Adobe Systems).
Tetramer analysis and intracellular cytokine staining. Peptide-
specific CD8 T cells and ex vivo production of IFN- or tumor necrosis
factor alpha (TNF-) were determined by tetramer staining, and intracel-
lular cytokine staining was performed as described previously (24, 28).
Detailed information on these procedures can be found in Text S1 in the
supplemental material.
Melanoma model. B16F10-GP melanoma cells expressing the LCMV
gp33 epitope (41) and parental B16F10 cells were kindly provided by H.
Pircher (University of Freiburg, Germany). Further information on tumor
protection assays can be found in Text S1 in the supplemental material.
Generation of humanDCs and ICS.DCswere generated frommono-
cytes isolated from peripheral blood mononuclear cells as described pre-
viously (55). Mature DCs were infected with Mel-A/EGFP-recombinant
HCoV-229E or GP-EGFP-recombinant HCoV-229E and incubated with
Mel-A-specific T cell clones as responder cells. Further details on in vitro
humanCD8T cell activation by transduced humanDCs can be found in
Text S1 in the supplemental material.
Statistical analysis.All statistical analyses were performed with Prism
4.0 (GraphPad Software Inc.). Data were analyzed with the nonpaired
Student t test under the assumption that the values followed a Gaussian
distribution. A P value of0.05 was considered significant.
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